FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428’s Potential for Best-in-Class PARG Inhibition
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitors Presentation also includes molecular structure and discovery data Initial data from an open-label Phase 1 study of FORX-428 in patients with […]
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
Basel, Switzerland, December 18, 2025 – FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
Basel, Switzerland, 11 August 2025 – FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response.
FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer
Basel, Switzerland, 26 February 2025 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR) pathways, announced today the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.
Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG
Basel, Switzerland, 15 May 2024 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Michael Kauffman as Chairman of the Board.
FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428
Basel, Switzerland, 3 May 2024 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR) pathways, announced today the nomination of its first preclinical development candidate, FORX-428, an inhibitor of Poly(ADP-ribose) glycohydrolase (PARG). FORX-428 has strong best-in-class potential and is being developed for the treatment of solid tumors. IND-enabling activities have already been initiated.
FoRx Therapeutics AG appoints Frank Zenke as Chief Scientific Officer
Basel, Switzerland, 01 August 2023 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Frank Zenke as Chief Scientific Officer.
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
Basel, Switzerland, 01 April, 2021 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Tarig Bashir as Chief Executive Officer.
FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry
Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.
FoRx Therapeutics AG Raises EUR 10 Million Seed Round
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Basel, Switzerland, 22 April, 2020 – FoRx Therapeutics AG (FoRx), the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways, today announced the closing of a EUR 10 million seed financing led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners) also joined the seed financing. The company also announces the appointment of Colin Goddard as Executive Chairman.